title: Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases.
abstract: Human cerebrospinal fluid (CSF) contains chromogranin A and B and secretogranin II which represent peptides secreted from neuronal large dense core vesicles. Within these vesicles these precursor peptides are at least partly processed to smaller peptides. We analysed the CSF levels of chromogranins/secretogranin by radioimmunoassay using specific antisera. The degree of their processing was characterized by molecular sieve column chromatography followed by radioimmunoassay. As previously shown secretogranin II is fully processed to smaller peptides including the peptide secretoneurin, whereas processing of chromogranin A was more limited. For chromogranin B we found in this study a high degree of processing comparable to that of secretogranin II. An analysis of CSF from patients with multiple sclerosis, essential tremor, Alzheimer and Parkinson disease, did not reveal any differences in proteolytic processing of chromogranins/secretogranin when compared to control CSF. We conclude that in the four diseases investigated there is no change in the proteolytic processing of the chromogranins/secretogranin within the large dense core vesicles. The absolute levels of chromogranins/secretogranin varied in CSF collected in different hospitals, however their relative ratios were remarkable constant. We suggest to use this ratio as a parameter to standardise CSF levels of other peptides, e.g. neuropeptides. In Parkinson patients the chromogranin A/secretogranin II ratio was significantly increased whereas in Alzheimer patients and those with essential tremor and multiple sclerosis no change of the ratios was observed. Apparently there are only limited changes in the biosynthesis, processing, secretion and CSF clearance of these peptides in pathological conditions.
authors.affiliation: Department of Pharmacology, University of Innsbruck, Austria.
authors.forename: U
authors.initials: U
authors.lastname: Eder
authors.forename: B
authors.initials: B
authors.lastname: Leitner
authors.forename: R
authors.initials: R
authors.lastname: Kirchmair
authors.forename: P
authors.initials: P
authors.lastname: Pohl
authors.forename: K A
authors.initials: KA
authors.lastname: Jobst
authors.forename: A D
authors.initials: AD
authors.lastname: Smith
authors.forename: J
authors.initials: J
authors.lastname: Málly
authors.forename: A
authors.initials: A
authors.lastname: Benzer
authors.forename: P
authors.initials: P
authors.lastname: Riederer
authors.forename: H
authors.initials: H
authors.lastname: Reichmann
authors.forename: A
authors.initials: A
authors.lastname: Saria
authors.forename: H
authors.initials: H
authors.lastname: Winkler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid; D002851:Chromatography, High Pressure Liquid; D053379:Chromogranin A; D002864:Chromogranins / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid; D009422:Nervous System Diseases / Q000134:cerebrospinal fluid*; D009479:Neuropeptides / Q000134:cerebrospinal fluid*; D010300:Parkinson Disease / Q000134:cerebrospinal fluid; D011506:Proteins / Q000032:analysis*; D011863:Radioimmunoassay; D014202:Tremor / Q000134:cerebrospinal fluid
chemical_list: C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins; D009479:Neuropeptides; D011506:Proteins